Hemofarm
↗Vršac, Serbia
Hemofarm is the leading pharmaceutical company in Serbia and the largest exporter of medicinal products in the region, operating as a key subsidiary of the German STADA Group since 2006. Founded in 1960, the company produces a vast portfolio of prescription (Rx) medicines, over-the-counter (OTC) drugs, and consumer healthcare products, including dietary supplements and vitamins.
The company serves as a strategic manufacturing and R&D hub for the STADA Group, with advanced production facilities across Serbia, Bosnia and Herzegovina, and Montenegro. Hemofarm is recognized for its high-volume manufacturing capabilities, producing nearly 8 billion tablets annually, and its commitment to sustainable development through ESG initiatives and modernization of its 'mega-factory' sites.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1000-5000
Revenue:$500M-$1B
Founded:1960
Ownership:subsidiary
Status:operating
FUNDING
Stage:Acquired
Total Raised:$15.8M
Investors:Bain Capital (via STADA), Cinven (via STADA)
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Biosimilars (mAbs), Oral solids, Injectables
Active Trials:12
Trial Phases:Phase 1: 2 | Phase 2: 3 | Phase 3: 7
FDA Approvals:5
EMA Approvals:25
CORPORATE STRUCTURE
Parent Company:STADA Arzneimittel AG
Acquired By:STADA Arzneimittel AG (2006-08-01)
Subsidiaries:Hemofarm d.o.o. Banja Luka, Hemomont d.o.o. Podgorica, STADA IT Solutions, Hemofarm Foundation
Key Partnerships:Roche (Marketing partner for Ocrelizumab in Serbia), Sanofi (Marketing partner for CHC brands like Buscopan and Dulcolax), CR Sanjiu (Consumer healthcare partnership in China)
COMPETITION
Position:Leader
Competitors:Krka, Teva (Pliva), Sandoz, Zentiva, Alkaloid
LEADERSHIP
Key Executives:
Ronald Seeliger - CEO
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Hemofarm. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.